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AIMS
Voriconazole (VCZ) exhibits wide intrapatient pharmacokinetic variability, which is disadvantageous because of its narrow
therapeutic range. A considerable part of this variation remains unexplainable, despite extensive knowledge of this drug. It is
hypothesized that inﬂammation has an impact on VCZ pharmacokinetics. In the present study, we investigated the correlation
between VCZ trough concentrations and various cytokines.
METHODS
A prospective single-centre analysis was performed in adult haematology patients receiving VCZ for possible, probable or proven
invasive fungal disease. A linear mixed model was built to explore the contribution of each of the seven pro- and anti-
inﬂammatory cytokines to VCZ trough levels. The Akaike information criterion (AIC) was used to determine the model that ﬁtted
the best.
RESULTS
Twenty-two patients, with a total of 143 combined samples of VCZ trough levels and cytokines, were included. A signiﬁcant
correlation (P < 0.005) was found between VCZ trough concentrations and interleukin (IL) 6, IL-8 and C-reactive protein (CRP).
IL-6 showed the lowest AIC, although differences with the other mediators were marginal.
CONCLUSION
VCZ trough concentrations correlate with IL-6, IL-8 and CRP levels but only moderately explain the variability in VCZ pharma-
cokinetics. Future prospective studies should be undertaken to conﬁrm these ﬁndings, and incorporate the data obtained into
pharmacokinetic models, to reﬁne the predictive behaviour.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Inﬂammation, as measured by C-reactive protein (CRP), has been associated with voriconazole (VCZ) exposure.
• It is argued that CRP can be used to predict exposure to VCZ, and helps to explain the pharmacokinetic variability of this
drug.
WHAT THIS STUDY ADDS
• We conﬁrmed the relationship between proinﬂammatory markers and VCZ trough concentrations but found large
intersubject variability in correlations. We believe that more in-depth mechanistic investigation into pro- and anti-
inﬂammatory markers is needed to resolve the impact on VCZ exposure.
• We also provided a more in-depth analysis incorporating other pro- and anti-inﬂammatory markers, in addition to CRP.
• We demonstrated that the correlation between inﬂammation and VCZ is weak and does not help to explain the large
pharmacokinetic variability.
Introduction
Voriconazole (VCZ) is a broad-spectrum triazole antifungal
agent that is widely used in the treatment of invasive fungal
disease (IFD), with pathogens of Aspergillus and Candida spe-
cies [1]. Treatment failure due to low VCZ trough concentra-
tions is likely to occur, while hepatotoxicity has been
associated with high VCZ trough concentrations [2, 3].
Large interpatient and intrapatient variations in VCZ trough
concentrations exist [2]. The wide intrapatient variation in
VCZ trough concentrations is particularly disadvantageous
because of the known narrow therapeutic range of this
agent [4]. Concomitant factors, such as the route of admin-
istration, drug–drug interactions, liver dysfunction and ge-
notypic variation in the genes of metabolic enzymes, are
known to contribute to this variation [5, 6]. However, a con-
siderable part of the intrapatient variability still remains
unexplained.
The metabolism of VCZ is regulated by liver enzymes,
mainly by the drug-metabolizing enzyme cytochrome P450
(CYP) 2C19, and to a lesser extent by CYP3A4 and CYP2C9
via oxidation [7–9]. N-oxide VCZ is the main circulating me-
tabolite of VCZ in the blood and is 100-fold less potent
against fungal pathogens than VCZ. Next to N-oxidation,
hydroxylation is another important pathway of VCZmetabo-
lism. Whereas CYP2C19 is responsible for the main part of
N-oxidation, CYP3A4 appears to play a more important role
in the hydroxylation pathway [9, 10]. Oxidation via ﬂavin-
containing mono-oxygenase could be responsible for the re-
maining part of metabolism via N-oxidation [11]. CYP2C19
harbours many polymorphisms, of which the poor
metabolizer phenotype has been investigated most exten-
sively. High VCZ concentrations have been associated with
the presence of the poor metabolizer phenotype [3]. How-
ever, genotyping in predicting VCZ trough levels is not rou-
tinely used in clinical practice [2]. Emerging evidence
actually indicates that inﬂammation inﬂuences the meta-
bolic phenotype of both CYP3A4 and CYP2C19 [12–14].
Most patients with IFD are severely immunocompro-
mised, and a considerably large subgroup suffers from a
haematological malignancy. The disease-intrinsic immuno-
deﬁciency, in combination with the treatment-induced im-
munosuppression, severely increases the risk of IFDs in
these patient [15]. Intensive chemotherapy, used for the treat-
ment of acute leukaemia and allogeneic stem cell transplanta-
tion (SCT), induces tissue damage, neutropenia and cellular
immune dysfunction, resulting in a profound inﬂammatory
response and the onset of fever.
C-reactive protein (CRP) is commonly used as a marker
reﬂecting the severity of inﬂammation, but is aspeciﬁc and
in fact is a surrogate marker of the acute phase response.
CRP is produced by hepatocytes, predominantly under the
transcriptional control of interleukin (IL) 6 [16]. Recently,
a signiﬁcant correlation between CRP and VCZ trough con-
centrations was reported [14, 17, 18]. As in vitro studies have
demonstrated that IL-6 and other upstream proinﬂammatory
cytokines downregulate CYP2C19 and CYP3A4 gene expres-
sion [19, 20], downregulation of these CYP enzymes by ele-
vated concentrations of IL-6 might cause an increase in VCZ
trough concentrations.
The purpose of the present study therefore was to
determine whether concentrations of various pro- and anti-
inﬂammatory cytokines correlate with VCZ trough
concentrations.
Methods
Patients and study design
The study was carried out in accordance with the applicable
rules concerning biomedical research using patient data.
Patient data were collected and analysed anonymously in a
prospective single-centre study of adult haematology pa-
tients (≥18 years of age) from the Radboud University Medical
Center (Nijmegen, the Netherlands). Ethical approval for ret-
rospective data collection was obtained. Patient data were el-
igible for analysis when patients were treated with VCZ dose
according to the label for a possible, probable or proven IFD
and underwent controlled sampling. IFD diagnosis was classi-
ﬁed according to European Organization for Research and
Treatment of Cancer (EORTC) criteria being possible, proba-
ble or proven [21]. Furthermore, underlying haematological
disease, the treatment received and basic characteristics such
as age, gender, height and weight were recorded, as well as
liver function tests [alanine transaminase (ALT), aspartate
aminotransferase (AST), lactate dehydrogenase (LDH),
gamma-glutamyl transferase (γ-GT), alkaline phosphatase
(ALP) and bilirubin (conjugated and unconjugated)]. Liver
function tests were only recorded if the interval between their
sampling time and the corresponding VCZ trough concentra-
tion sampling time was <24 h. The hospital information
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system (HIS) was used to retrieve data on dosing regimens
(dose, time of dose and route of administration) and to re-
trieve data on co-medications that might interact with VCZ.
VCZ samples were excluded if co-medications that were
known to inﬂuence VCZ metabolism were taken simulta-
neously. Differences in time within patient sampling and be-
tween patient sampling were taken into account using a
speciﬁc statistical analysis that corrects for different values
of time.
VCZ trough concentration determination
Only samples for VCZ trough concentrations determination
were used. A VCZ concentration was conﬁrmed to be a valid
trough concentration when this was recorded in the HIS.
VCZ trough concentrations were monitored twice weekly in
the ﬁrst weeks of treatment, followed by weekly concentra-
tions from the third week, allowing dose modiﬁcations based
on the results of therapeutic drug monitoring. VCZ trough
concentration was determined by a validated routine ultra-
high performance liquid chromatography–ultraviolet plasma
assay, as described in [22]. The lower detection limit of this
assay was 0.05 mg l–1 and the upper detection limit was
10 mg l–1. If VCZ trough concentrations were above 10 mg
l–1, plasma samples were diluted with commercial blank
blood plasma to reach a concentration lower than 10 mg l–1.
Cytokine concentration determination
Cytokine and CRP samples were stored at80°C immediately
after collection. Plasma concentrations of the proinﬂamma-
tory cytokines tumour necrosis factor-alpha (TNF-α), IL-1β,
IL-6, IL-8 and interferon-gamma (IFN-γ), as well as the anti-
inﬂammatory cytokines IL-1RA and IL-10, were analysed
batchwise in plasma obtained from lithium–heparin
anticoagulated blood using a simultaneous Luminex assay ac-
cording to the manufacturer’s instructions (Milliplex;
Millipore, Billerica, MA, USA). The lower detection limit of
the assay was 6.4 pg ml–1 for all measured cytokines. The in-
traday coefﬁcient of variation was between 1.6% and 2.6%,
whereas the interday coefﬁcient of variation ranged from
3.5% to 18.3%. Accuracy was above 94.9 for all inﬂammatory
markers.
CRP was determined by means of the COBAS auto-
analyzer (Roche Diagnostics, Mannheim, Germany) using
the C-Reactive Protein Gen 3 test. The intraday coefﬁcient
of variation at 7 mg l–1 and 48 mg l–1 was 0% and 2%, respec-
tively. Accuracy was>99.88% at low concentrations and total
imprecision was 2.5%.
Statistical analysis
To explore the possible associations of interest, we calculated
the Pearson correlation coefﬁcient between the log-
transformed concentrations of each of the seven cytokines
and the VCZ trough concentrations, also logarithmically
transformed. These overall correlations do not adjust for the
repeated character of the observations within patients over
time. To account for correlations between repeated log-VCZ
trough concentrations within a patient, linear mixed models
for repeated measurements were applied with Gaussian serial
covariance structure in combination with a random
intercept.
These models also accounted for missing data, provided
that missing data were missing at random. For each cytokine
and CRP, a linear mixed model was used to analyse its effect
on VCZ. To correct for possible confounders, we incorporated
ﬁxed effects: dose per kg, route of administration (oral/intra-
venous), ALT, AST, LDH, γ-GT, ALP and bilirubin (conjugated
and unconjugated). These factors were chosen at the discre-
tion of the researchers. To compare the predictive powers
with respect to VCZ concentrations of the cytokines and
CRP, we used the ﬁt statistics Akaike information criterion
(AIC).
Values lower than the detection limit were treated asmiss-
ing values. Two-sided P-values <0.05, uncorrected for multi-
ple testing, were considered to indicate statistical
signiﬁcance. The SAS software package (version 8.2, Huizen,
The Netherlands) was used to ﬁt the models.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org,thecommon portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY [23], and are permanently archived in
the Concise Guide to PHARMACOLOGY 2017/18 [24, 25].
Results
Patient characteristics
A total of 22 haematology patients were included in our
study. The baseline patient characteristics are depicted in
Table 1. Sixteen out of 22 patients were classiﬁed as having
probable invasive pulmonary aspergillosis (IA), and ﬁve with
possible pulmonary IA. One patient was suspected to have an
IA but did not match the criteria in the end.
VCZ trough concentrations
In all, 268 VCZ concentrations were available from our pa-
tient cohort. Of these, 173 were conﬁrmed to be valid VCZ
trough concentrations. A total of 143 of the VCZ trough con-
centrations matched with samples that were available for cy-
tokine and CRP determination. A median of seven samples
per patient was available, with two patients accounting for
only one determination per patient. The median VCZ trough
concentration was 2.3 (1.5–3.7) mg l–1 and the median VCZ
duration of treatment was 21 [3–61] days (see Table 2). Dose
modiﬁcation as a result of therapeutic drug monitoring was
performed in 14 patients.
Determination of levels of cytokines and CRP,
and liver function tests
In all 143 samples that were available for VCZ trough concen-
tration determinations, at least one cytokine concentration
was detectable. This resulted in different numbers of combi-
nations between VCZ trough concentrations and speciﬁc cy-
tokines. A total of 139 pairs of VCZ and IL-8, 134 pairs of
VCZ and CRP, and 101 pairs of VCZ were available. An over-
view of all measured laboratory parameters can be found in
Table 2.
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Correlations between inflammatory markers
and VCZ trough concentrations
Of the seven cytokines, only IL-6 and IL-8 turned out to have
a signiﬁcant overall association with VCZ trough concentra-
tions: IL-6: r = 0.46, P < 0.0001, 100 observations; IL-8: r =
0.42, P < 0.0001, 138 observations (Figure 1).
Results on linear mixed-model analyses pointed in the
same direction: only IL-6 (P = 0.0003) and IL-8 (P = 0.0002)
were signiﬁcantly related to VCZ trough concentrations after
correction for dose per kg and conjugated bilirubin. There
was no need to correct for the potential confounders ALT,
AST, LDH, γ-GT, ALP and unconjugated bilirubin.
CRP levels showed an overall correlation with VCZ trough
concentrations: r = 0.53, P < 0.0001, 133 observations
(Figure 2).
Linear mixed-model analysis showed that CRP levels were
associated with VCZ trough concentrations after correction
for dose per kg and conjugated bilirubin: P < 0.0001. The re-
sults for VCZ, CRP and IL-6 concentrations per patient are
shown in Figures 3 and 4, which show the differences be-
tween individuals in the correlation between VCZ trough
concentration and IL-6 and CRP.
Comparing the ability of cytokines to predict
VCZ levels, in comparison with CRP
To compare the associations of Il-6 and IL-8, respectively,
with VCZ trough concentrations on the one hand, and
that of CRP with VCZ trough concentrations on the other,
we ﬁtted the above-mentioned models on the same subset,
consisting of all those observations with nonmissing
values for VCZ, Il-6, IL-8, CRP, conjugated bilirubin and
dose per kg at the same time points (Table 3). This
resulted in a total of 82 observations containing no miss-
ing values.
Inspection of the AICs of these three models, ﬁtted on
the same dataset of 82 observations, showed that the ﬁt of
the model with CRP (AIC = 172.5) was poorer than that of the
models containing IL-6 (AIC = 169.6) or IL-8 (AIC =
170.6), although the differences were marginal.
Discussion
In the present study, we examined a panel of seven cytokines,
both pro- and anti-inﬂammatory, in speciﬁc models, for their
correlation with VCZ trough concentrations. The levels of
two of these proinﬂammatory cytokines, IL-6 and IL-8, corre-
lated signiﬁcantly with VCZ trough concentrations. We
Table 1
Baseline characteristics
Parameter Results (n = 22)
Characteristics
Female gender 9 (41%)
Age (years), median (range) 53 (47–61)
BMI, median (range) 25.8 (21.1–27.9)
Underlying diseases
Acute myeloid leukaemia 10 (45%)
Myelodysplastic syndrome 3 (14%)
Multiple myeloma 2 (9%)
Other haematological malignancies 7 (32%)
Diagnosis of invasive fungal disease
Possible IA 5 (32%)
Probable IA 16 (73%)
Other (i.e. pulmonary Rhizomucor) 1 (5%)
Treatment
Chemotherapy 22 (100%)
Allogeneic SCT 13 (59%)
Data are presented as median (interquartile range) or as n (%). BMI,
body mass index; IA, invasive aspergillosis; SCT, stem cell
transplantation
Table 2
Laboratory parameters
Laboratory parameters
Parameter n Value
VCZ trough (mg l–1) 173 2.3 (1.5–3.7)
VCZ matches (pp) 143 7 (3–10)
Duration of VCZ follow-up (days) 22 21 (3–61)
Cytokines
IFN-γ (pg ml–1) 48 15 (10–29)
IL-10 (pg ml–1) 92 35 (12–66)
IL1-RA (pg ml–1) 76 34 (18–106)
IL-1β (pg ml–1) 4 9.5 (8.5–11)-
Il-6 (pg ml–1) 101 32 (12–80)
IL-8 (pg ml–1) 139 54 (22–122)
TNF-α (pg ml–1) 130 26 (15–44)
Liver function tests
ALT (U l–1) 136 35 (20–71)
AST (U l–1) 135 33 (22–60)
LDH (U l–1) 134 397 (259–666)
γ-GT (U l–1) 134 178 (62–443)
ALP (U l–1) 135 123 (89–179)
Bilirubin (total) (μmol l–1) 126 11 (8–20)
Bilirubin (unconjugated) (μmol l–1) 37 15 (10–32)
CRP (mg l–1) 134 37 (12–75)
Data are presented as median (interquartile range). ALP, alkaline
phosphatase; ALT, alanine aminotransferase; AST, aspartate ami-
notransferase; CRP, C-reactive protein; GT, glutamyl transferase;
IFN, interferon; IL, interleukin; LDH, lactate dehydrogenase; pp, per
patient; TNF, tumour necrosis factor; VCZ, voriconazole
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corrected for other known concomitant factors. The correla-
tions between VCZ and IL-6 levels, and between VCZ and
IL-8 levels were modest.
Our results highlight that proinﬂammatory markers only
partly explain the intrapatient variability in VCZ. A relation-
ship levels of pro-inﬂammatoiry cytokines and decreased
expression of CYP enzymes, and thereby higher concentra-
tions of several drugs, has previously been suggested [26].
Furthermore, a correlation between VCZ and inﬂammation,
reﬂected by CRP levels, has been reported [18, 27]. The possi-
ble relationship between upregulation of VCZ and speciﬁc
proinﬂammatory markers had not yet been described.
Recently, a study with a comparable design and patient group
was published, using another linear mixed model to deter-
mine the association of CRP with VCZ concentrations [17].
We used a different type of linear mixed model because of
the skewness of our data, which made log-transformation
essential. In our opinion, our model ensured a better ﬁt for
showing a correlation between VCZ trough and
cytokine/CRP concentrations. The Gaussian serial covariance
structure in combination with a random intercept takes into
account the fact that observations within a patient decrease
if the time between observations increases. This resulted in
lower values of AIC compared with using other approaches
[17]. The lower values of the AIC indicate a better ﬁt of our
data in this model. To account for correlations between
repeated log-VCZ trough concentrations within a patient,
linear mixed models for repeated measurements were applied
with Gaussian serial covariance structure in combination
with a random intercept. In addition to the Gaussian serial
covariance structure, we also explored the use of ﬁrst-order
autoregressive and exponential serial covariance structures.
As these structures resulted in higher values of AIC,
indicating a poorer ﬁt, we decided not to use them in the
present study.
The conﬁrmation of the correlation between IL-6 and
VCZ levels is interesting because it might imply that a higher
immune response to IFD enhances the toxic effects of VCZ
treatment. Patients suffering from IFDs produce many proin-
ﬂammatory cytokines as a result of the infection and, in addi-
tion, mucosal barrier injury and graft-vs.-host disease result in
increased levels of proinﬂammatory cytokines, which subse-
quently can result in the downregulation of CYP enzymes.
This results in higher VCZ concentrations, with the likeli-
hood of greater effectiveness in killing the mould, but at the
expense of toxicity for the patient. The inﬂammatory re-
sponse in our population was fairly modest, with an average
CRP level of 37 mg l–1 (Table 2). It remains to be investigated
whether the levels of pro-inﬂammatoiry cytokines on the
downregulation of VCZ metabolism.
IL-6 is a cytokine that has effects not only on immune
cells, but also on liver cells [28]. It ﬁrstly binds to its receptor
(IL-6R), then recruits glycoprotein 130 (gp130) and forms a
complex that subsequently activates signal transducer and
activator of transcription 3 (STAT3), and leads to transcrip-
tion [29]. IL-6R is expressed in only a limited number of cells
– mainly hepatocytes, macrophages and neutrophils [29].
Other cells in the host can also respond to IL-6 but will acti-
vate gp130 because IL-6 and soluble IL-6R form a complex
that circulates and binds to gp130, which is called trans-
signalling [30]. Hepatocytes express abundant gp130 and
therefore can be activated directly and via trans-signalling,
underscoring the signiﬁcant impact that IL-6 can have on he-
patocytes [31]. In the setting of patients with IFD that are
Figure 1
(A) Voriconazole (VCZ) concentrations (mg l–1) vs. interleukin (IL) 6
(pg ml–1) levels. (B) VCZ (mg l–1) vs. IL-8 levels (pg ml –1)
Figure 2
Voriconazole (VCZ) concentrations (mg l–1) vs. C-reactive protein
(CRP) levels (mg l–1)
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Figure 3
Voriconazole (VCZ) concentrations (mg l–1) (dotted line) and C-reactive protein (CRP) levels (mg ml–1) (continuous line) vs. time (days) of VCZ
treatment per individual patient (two patients were excluded because absence of repeated measurements over time)
Figure 4
Voriconazole (VCZ) concentrations (mg l–1) (dotted line) and interleukin (IL) 6 levels (pg ml–1) (continuous line) vs. time (days) of VCZ treatment
per individual patient (two patients were excluded because absence of repeated measurements over time)
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treated with VCZ, IL-6 could still be beneﬁcial for the host by
enhancing the treatment of IFD through its effects on hepato-
cytes, despite being ineffective in optimizing host responses
against the infection. As the effects of IL-6 are dependent on
STAT3, it is tempting to speculate that other signalling cas-
cades that modulate STAT3 activity might also play a signiﬁ-
cant role in regulating VCZ metabolism in hepatocytes.
As suggested, in vitro studies have clearly shown a direct
inﬂuence of IL-6 on CYP2C19 and CYP3A4 transcription
and expression. Studies that investigated the inﬂuence of IL-
6 on different CYP enzymes demonstrated that IL-6-mediated
downregulation is more pronounced for CYP3A4 than for
CYP2C19. This could play an important role in poor
metabolizers because the expected main responsible meta-
bolic pathway in these metabolizers is the hydroxylation
route via CYP3A4. According to this theory, poor
metabolizers of CYP2C19 with high IL-6 concentrations
should have even higher VCZ trough concentrations than
poor metabolizers without high IL-6 concentrations. The im-
pact of inﬂammation in patients who use VCZ could thereby
be even bigger in poor metabolizers. Unfortunately, we were
not able to determine the genotype of our patients, so we
could not investigate this hypothesis.
To conﬁrm the impact of the immune response on the
clearance pathways of VCZ, the metabolic ratio of VCZ and
N-oxide VCZmight have providedmore information. Knowl-
edge on shifts in this ratio would have helped to determine
the downregulation of metabolic processes involved in VCZ
turnover and further substantiate the hypothesis of a reduc-
tion in clearance caused by the inﬂammatory response. Un-
fortunately, this information was not available from our
cohort.
We also found that IL-8 concentrations were associated
with VCZ trough concentrations. There are several possible
explanations for the similar relationships between IL-8 and
VCZ, and between IL-6 and VCZ. First, similar to IL-6, IL-8
might have direct effects on CYP enzymes. However, in con-
trast to the in vitro studies on IL-6 and CYP enzymes, there
are no reports on the effects of IL-8 on these enzymes.
Secondly, the production of both IL-6 and IL-8 is induced by
recognition of pathogen-associated molecular patterns and
under the transcriptional control of, among others, the
master inﬂammatory transcription factor, nuclear factor κB
[32–34]. Therefore, the relationship between IL-8 and VCZ
might be an epiphenomenon, caused by the fact that IL-8 is
induced alongside IL-6 in this patient group, but has no direct
effects on CYP enzymes. This is in line with an inter-
correlation we found between IL-6 and IL-8, but which we
did not show in our results. Regarding the known direct effect
of IL-6 on CYP enzymes, we hypothesize that IL-6 might play
amore important role in VCZmetabolism by downregulating
CYP enzymes, although the AIC for IL-6 was only marginally
better than that for IL-8, which cannot serve as a conﬁrma-
tion of this hypothesis.
The correlation between CRP and VCZ trough concentra-
tions will be more useful in clinical practice compared with
the use of IL-6 or IL-8 levels. The beneﬁt of using these cyto-
kine levels is that they provide more downstream-selective
information on inﬂammation. CRP levels are measured more
frequently than IL-6 or IL-8 in everyday healthcare settings,
and at a lower cost than for these cytokines. As such, CRP
might be easier to use in clinical practice, keeping in mind
that the correlation between CRP and VCZ alone is not
enough to explain the speciﬁc contribution of the high
intrapatient variability in VCZ trough concentrations.
A possible limitation to the study was the time difference
between the actual determination of VCZ trough concentra-
tions and measurement of cytokine/CRP levels. Sampling
and determination of VCZ trough concentrations took place
on the same day, but measurement of cytokine levels took
place after a period of 2–5 years’ storage at 80°C. The stabil-
ity of different cytokines has not been investigated for a pe-
riod longer than 2 years [35]. However, even if the cytokine
concentrations were to be lower than expected, they would
still allow us to determine whether VCZ concentrations can
be predicted by these cytokine levels owing to an equally rel-
evant decay over time. By using our linear mixed model, the
speciﬁc value of the cytokine concentrations is less important
than the relative comparison with increased or decreased
VCZ trough concentrations.
Finally, as can be seen in Figure 3, VCZ and proinﬂamma-
tory markers mimic each other well in some cases but poorly
in other cases. We could not establish a plausible cause for
this, such as dose adaptations. No signiﬁcant difference was
found between patients undergoing therapeutic drug moni-
toring and those who did not.
We realize that the study might have beneﬁted from a
larger sample size, to determine the speciﬁc contribution of
IL-6 or IL-8 to VCZ trough concentrations. Despite the pro-
spective design of our study, samples had to be excluded from
analysis. Ideally, samples of VCZ trough and cytokines are
available more frequent (for instance at least three times
weekly) and with fully identical timing of both cytokines as
well as voriconazole trough concentration. A study with a
Table 3
Statistical comparison between the log-IL-6, log-IL-8 and log-CRP models
Estimated regression
coefﬁcient Intercept Dose per kg Log-bilirubin level
Log-IL-6, log-IL-8
or log-CRP levels
Akaike Information
Criteriona
Number of
observations
Model with log-IL-6 2.1990 P = 0.0010 0.4162 P = 0.0002 0.3393 P = 0.0283 0.2254 P = 0.0004 169.6 82
Model with log-IL-8 2.8777 P = 0.003 0.4728 P < 0.0001 0.3766 P = 0.0199 0.2881 P = 0.0014 170.6 82
Model with log-CRP 2.2546 P = 0.0012 0.3754 P = 0.0011 0.3685 P = 0.0157 0.2419 P = 0.0005 172.5 82
CRP, C-reactive protein; IL, interleukin
aSmaller values are better
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larger patient cohort and focusing on altered clearance pat-
terns (including metabolite information) is required to pre-
dict the inﬂuence of speciﬁc cytokines more precisely. A
prospective study should be performed in two groups of com-
parable healthy volunteers, one group receiving intravenous
VCZ without stimulation of proinﬂammatory cytokine pro-
duction, and the other receiving intravenous VCZ with stim-
ulation of proinﬂammatory cytokine production – for
example, with lipopolysaccharide. Both groups should have
similar patient characteristics, including a conﬁrmed exten-
sive metabolizer phenotype of CYP2C19.
By measuring IL-6, IL-8, CRP and VCZ trough concentra-
tions, we were able to determine the potential contribution
of IL-6 and IL-8 in the upregulation of VCZ trough concentra-
tions and compare this to the contribution of CRP levels. This
outcome should be tested in future pharmacokinetic model-
ling exercises as a relevant covariate on clearance. This might
help us to retrieve more information on the currently unex-
plained differences within a patient over time. If this result
proves valid, it will help us to make valid recommendations
for dose adaptation, taking this ﬁnding into account. In con-
clusion, VCZ trough concentrations show a signiﬁcant but
modest correlation with IL-6, IL-8 and CRP levels. Future
studies should investigate this prospectively, and incorporate
the data obtained into pharmacokinetic models to reﬁne this
predictive behaviour.
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